Immatics (IMTX) Non-Current Deferred Tax Liability (2022 - 2025)
Immatics' (IMTX) quarterly Non-Current Deferred Tax Liability came in at $4.4 million in Q4 2025, down 28.55% year-on-year from $6.2 million in Q4 2024, and up 3.06% quarter-over-quarter from $4.3 million in Q3 2025.
Immatics (IMTX) Non-Current Deferred Tax Liability (2022 - 2025) Analysis & Trends
Immatics has disclosed Non-Current Deferred Tax Liability across 4 years of filings, most recently posting $4.4 million for Q4 2025.
- Non-Current Deferred Tax Liability for Q4 2025 came in at $4.4 million, down 28.55% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.4 million (down 28.55% YoY), and the FY2025 annual result was $4.3 million, down 30.65% from the prior year.
- Non-Current Deferred Tax Liability came in at $4.4 million for Q4 2025 at Immatics, up from $4.3 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $10.0 million in Q4 2022 to a low of $3.7 million in Q3 2024.
- The 4-year median for Non-Current Deferred Tax Liability is $5.6 million (2024), against an average of $6.0 million.
- Peak annual rise in Non-Current Deferred Tax Liability reached 16.59% in 2025, while the deepest fall reached 39.56% in 2025.
- Immatics' Non-Current Deferred Tax Liability stood at $10.0 million in 2022, then dropped by 19.75% to $8.0 million in 2023, then retreated by 22.79% to $6.2 million in 2024, then retreated by 28.55% to $4.4 million in 2025.
- The last three Non-Current Deferred Tax Liability figures came in at $4.4 million (Q4 2025), $4.3 million (Q3 2025), and $4.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Immatics | 14.67 Bn | 14.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.43 Mn |
| Dec 31, 2025 | 4.43 Mn |
| Sep 30, 2025 | 4.30 Mn |
| Sep 30, 2025 | 4.30 Mn |
| Jun 30, 2025 | 4.31 Mn |
| Jun 30, 2025 | 4.31 Mn |
| Mar 31, 2025 | 5.06 Mn |
| Mar 31, 2025 | 5.06 Mn |
| Dec 31, 2024 | 6.20 Mn |
| Dec 31, 2024 | 6.20 Mn |
| Sep 30, 2024 | 3.69 Mn |
| Sep 30, 2024 | 3.69 Mn |
| Jun 30, 2024 | 7.13 Mn |
| Jun 30, 2024 | 7.13 Mn |
| Mar 31, 2024 | 7.23 Mn |
| Mar 31, 2024 | 7.23 Mn |
| Dec 31, 2023 | 8.03 Mn |
| Dec 31, 2023 | 8.03 Mn |
| Dec 31, 2022 | 10.01 Mn |
| Dec 31, 2022 | 10.01 Mn |